Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ927MR)

This product GTTS-WQ927MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ927MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7609MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ15693MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ4635MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ14294MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ15340MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ5009MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ5510MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ6650MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DI-17E6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW